Condition: Cancer · Solid Tumor, Adult · Cancer Metastatic · Sponsor: Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors.
This description comes directly from the study's public registry record.
radhika Shah, MD · 1 984 459 5523 · radhika.shah@syneoshealth.com
Always discuss trial participation with your own doctor first.
| Horizon Oncology Research, LLC, | Lafayette, Indiana, United States | Completed |
| START | San Antonio, Texas, United States | Completed |
| UT Health | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04443088